Patient satisfaction, efficacy and safety of combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000012697
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have history of diabetic ketoacidosis, or diabetic coma in the past 6 months 2) Patients who are pregnant or in lactation period 3) Patients with serious infectious disease, before operation, serious trauma 4) Patients who receive steroid therapy 5) Patients with severe liver dysfunction 6) Patients with type 1 diabetes 7) Patients with disorder of insulin secretion whose fasting serum C-peptide <0.5ng/ml 8) Patients with hypersensitivity to these medicines 9) Patients who have history of pancreas disease 10) Patients who have history of cancer 11) Patients receiving with GLP-1 receptor agonist or he DPP-4 inhibitor in the past 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diabetes Treatment Satisfaction Questionnaire(DTSQ) at 0 and 12 weeks after switching from multiple insulin injection therapy to combination therapy with lixisenatide and basal insulin
- Secondary Outcome Measures
Name Time Method The daily profile of blood glucose, changes of HbA1c and body weight at 0 and 12 weeks after switching from multiple insulin injection therapy to combination therapy with lixisenatide and basal insulin Incidence of hypoglycemia